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Maternal Inheritance of a Promoter
Variant in the Imprinted PHLDA2 Gene
Significantly Increases Birth Weight
Miho Ishida,1 David Monk,1,5 Andrew J. Duncan,1 Sayeda Abu-Amero,1 Jiehan Chong,1,6
Susan M. Ring,2 Marcus E. Pembrey,1,2 Peter C. Hindmarsh,1 John C. Whittaker,3 Philip Stanier,4
and Gudrun E. Moore1,*
Birth weight is an important indicator of both perinatal and adult health, but little is known about the genetic factors contributing to its
variability. Intrauterine growth restriction is a leading cause of perinatal morbidity and mortality and is also associated with adult
disease. A significant correlation has been reported between lower birth weight and increased expression of the maternal PHLDA2 allele
in term placenta (the normal imprinting pattern wasmaintained). However, a mechanism that explains the transcriptional regulation of
PHLDA2 on in utero growth has yet to be described. In this study, we sequenced the PHLDA2 promoter region in 263 fetal DNA samples
to identify polymorphic variants. We used a luciferase reporter assay to identify in the PHLDA2 promoter a 15 bp repeat sequence (RS1)
variant that significantly reduces PHLDA2-promoter efficiency. RS1 genotyping was then performed in three independent white Euro-
pean normal birth cohorts. Meta-analysis of all three (total n ¼ 9,433) showed that maternal inheritance of RS1 resulted in a significant
93 g increase in birth weight (p ¼ 0.01; 95% confidence interval [CI] ¼ 22–163). Moreover, when the mother was homozygous for RS1,
the influence on birthweight was 155 g (p¼ 0.04; 95%CI¼ 9–300), which is a similarmagnitude to the reduction in birth weight caused
by maternal smoking.Very low birth weight shows a strong association with
perinatal mortality and morbidity and is linked to an
increased risk of developing adulthood diseases, such as
obesity and type 2 diabetes (MIM 125853).1,2 Fetal growth
relies on an effective nutrient supply from the mother to
the fetus via the placenta; this nutrient supply is in-
fluenced by a complex interrelationship between the
environment and genetics. Of particular interest are
imprinted genes, which show expression from only one
allele in a parent-of-origin dependent manner. Genomic
imprinting is found almost exclusively in placental
mammals. Its evolution is probably best explained by
the ‘‘conflict hypothesis,’’ which suggests that paternally
expressed imprinted genes promote fetal growth and
ensure inheritance of the paternal genome to successive
generations, whereas maternally expressed imprinted
genes limit growth in order for the mother to survive
and reproduce again.3
PHLDA2 (MIM 602131) encodes the pleckstrin
homology-like domain, family A, member 2 protein and
is a maternally expressed imprinted gene found in one of
the most extensively studied imprinting clusters in human
chromosomal region 11p15.5. Consistent with the
‘‘conflict hypothesis,’’ Phlda2-null mice exhibit placenta
overgrowth, whereas doubling the Phlda2 expression in
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The Amby a 13% reduction in fetal weight; both of these findings
suggest that Phlda2 has a growth-suppressing role.4,5 In hu-
mans, PHLDA2 is expressed in a variety of tissues but is
predominantly expressed in the villous cytotrophoblast
of the placenta throughout gestation,6,7 and upregulation
has been observed in intrauterine growth restriction
(IUGR) placentas.8–10 This complements our previous
finding that PHLDA2 expression is significantly higher in
the term placenta of lower-birth-weight babies.11 However,
sequence analysis of all informative samples in the ‘‘Moore
cohort’’ of white European normal births confirmed that
only maternal, monoallelic PHLDA2 expression was
present.11 This indicates that loss of imprinting (LOI) was
not responsible for the increased PHLDA2 expression and
suggests that additional regulatory mechanisms, including
the PHLDA2 promoter, other than imprinting must be
involved.
In this study, we examined the PHLDA2 promoter region
for genetic polymorphisms that might affect PHLDA2 tran-
scriptional activity and therefore could affect birth weight.
From the Moore cohort (n ¼ 263), recruited from Queen
Charlotte and Chelsea Hospital,11 we sequenced a ~2 kb
upstream region beginning at the transcription start site
and overlapping the promoter CpG island. The UCSC
Genome Browser (build GRCh37/hg19) listed 20 SNPs,
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Figure 1. Sequence Electropherograms
Showing the 15 bp RS in the PHLDA2 Promoter
Region
RS1/RS1 homozygous, RS2/RS2 homozygous,
and RS1/RS2 heterozygous sequences are shown.
Each black bar represents the location of a single
15 bp copy. The start of the overlapping sequence
in the heterozygous sample is indicated by the
black arrow and dotted bars.However, none of these SNPs were identified in this cohort,
suggesting that they either are rare in the white European
population or have not been accurately validated. We only
detected one variable sequence: a tandem 15 bp (50-GGGG
CGGGGAGGGGC- 30; bp 4,934–4,967 of NG_009266.1)
repeat sequence (RS) variant present 48 bp upstream of
the PHLDA2 transcription start site (Figure S1, available
online). The tandem repeat (RS2) is most common (it is
present in 87% of chromosomes), and the minor allele is
a single copy (RS1) that is found in the remaining 13% of
chromosomes (Figure 1). In addition, RS1 was not found
to be in linkage disequilibrium (LD) with nearby SNPs
rs3847646 (located ~3 kb upstream) or rs13390 or
rs1056819 (present within PHLDA2 exons 1 and 2,
respectively).
We investigated the effect of the PHLDA2 RS on the
gene’s promoter activity by transiently transfecting lucif-
erase reporter constructs into the transformed human
embryonic kidney (HEK) 293T cell line and the human
trophoblast cell line 1 (TCL-1). We made the promoter
constructs by cloning 300 bp (with the use of HindIII
and Xho1) and 600 bp (with the use of HindIII and Sac1)
DNA fragments upstream of the PHLDA2 start site and in-
serting them into the pGL3.1-Basic vector (Promega, UK).
These sequences contained either RS1 or RS2. RS1 showed
significantly lower PHLDA2 promoter activity for both the
300 bp (74% decrease; t test, p ¼ 0.004) and 600 bp (42%
decrease; t test, p ¼ 0.001) constructs (Figure 2). The exper-
iments were performed in duplicate for HEK293T cells and
in triplicate for TCL-1 cells (Figure S2), and each assay
included six replicates. TFSEARCH (Transcriptional Factor
Search) shows that the RS2 allele potentially harbors four
SP1 and two MZF1 binding sites. However, losing a 15 bp
copy (RS1) removes three of these sites, suggesting the
possibility that the number of available transcription-
factor binding sites might be important for promoter
efficiency.
Given that high expression of PHLDA2 is associated with
lower birth weight11 and that RS1 reduces the PHLDA2716 The American Journal of Human Genetics 90, 715–719, April 6, 2012promoter efficiency in vitro, we investi-
gated whether RS1 could be associated
with increased birth weight. Because
PHLDA2 is maternally expressed and pater-
nally silenced, RS1 homozygotes and
heterozygotes with a maternally inherited
RS1 were grouped and deemed the ‘‘RS1
effect group.’’ RS2 homozygotes and hetero-zygotes with a paternally inherited RS1 were named the
‘‘unaffected group’’ (Table S1). We assessed the parental
origin of the RS1 allele in the heterozygous babies by
genotyping their corresponding parental DNA samples.
Uninformative cases were those in which both parents
were heterozygotes.
We first genotyped the parental DNA samples corre-
sponding to the heterozygous babies in the Moore cohort,
and 28 babies were revealed to have maternally inherited
RS1 (Table 1). To investigate the effect of maternally in-
herited RS1 on birth weight, we applied a linear-regression
model and corrected for the following covariates: the
gender of the baby,maternal weight, gestational age, parity
and maternal diabetes, hypertension, and smoking habits
(Table S2). A two-tailed test was used throughout; p values
were based on Wald tests, and standard residual plots were
examined and showed no evidence of departure from
model assumptions. This analysis showed that babies in
the RS1 effect group tended to have an average birth
weight 122 g higher than that of the babies in the unaf-
fected group (p ¼ 0.15; 95% confidence interval [CI] ¼
43–286) (Table 1). We then carried out the same analysis
on the UCL-FGS cohort (baby-parent trios, n ¼ 385) from
the University College London Fetal Growth Study.12
This produced a similar trend to the Moore cohort: babies
in the RS1 effect group (n ¼ 16) were on average 68 g
heavier (p ¼ 0.61; 95% CI ¼ 196–332) (Table 1). The
reproducibility of this trend suggests a potentially valid
finding despite the fact that statistical confidence could
not be achieved because too few individuals (approxi-
mately 13%) had maternal RS1 (Table 1).
To address this, we then introduced a third and larger
collection, the ALSPAC cohort (n ¼ 8,785) from the Avon
Longitudinal Study of Parents and Children study.13
Because this cohort only includes samples from the
mother and child and because PHLDA2 is a maternally ex-
pressed transcript, the RS1 effect group (n¼ 179) consisted
of homozygous RS1/RS1 babies and heterozygous babies
with homozygous RS1/RS1 mothers (Table S3). Using the
Figure 2. The Effects of RS1 and RS2 on PHLDA2
Promoter Efficiency in HEK 293T Cells
The bars indicate the firefly luciferase expression
relative to Renilla luciferase activity in HEK 293T
cells for the 300 bp and 600 bp constructs with
either RS2 or RS1. Luciferase activity was
measured 30 hr after transfection. This data
shows the mean of six replicate samples 5 SEM
(standard error of the mean). Asterisks represent
p < 0.05.same analysis as previously described, we found that
maternal inheritance of RS1 in this cohort results in an
average 88 g increase in the baby’s birth weight (p ¼
0.03; 95% CI ¼ 6–170) (Table 1). We then performed
a meta-analysis to combine the data from all three cohorts
by using both fixed- and random-effects models. The
results from both models showed that babies inheriting
maternal RS1 have a 93 g heavier birth weight (p ¼ 0.01;
95% CI¼ 22–163) (Figure 3). No evidence of heterogeneity
was found across the studies (p ¼ 0.92, I2 ¼ 0%). In addi-
tion, no evidence of association was found between birth
weight and paternally inherited RS1, consistent with the
imprinting of PHLDA2. Medical records and clinical data
for all three cohorts were obtained with informed consent,
and the study was approved by the ALSPAC Law and Ethics
Committee and the local research ethics committees of
Hammersmith and Queen Charlotte’s and Chelsea
Hospital Trust and University College London.
The meta-analysis indicated that the fetal genotypes had
a direct influence on the babies0 birth weight; therefore, weTable 1. Baby Genotypes and Influence on Birth Weight: Individual Studies and Meta-A
Study RS2/RS2 RS1/RS1 RS2/RS1 Pa Mb RS1 Effect Group
Moore 193 4 66 22 24 28
UCL-FGS 292 5 88 20 11 16
ALSPAC 6,649 128 2,008 465 51 179
Combinedc 7,134 137 2,162 507 86 223
The RS1 effect group consists of babies with maternally inherited RS1. RS1/RS2 heterozygous babies w
origin of RS1 and were therefore removed from the analysis. All effect estimates (g) have been adju
weight, gestational age, maternal smoking, diabetes, and hypertension. The observed genotype freq
berg equilibrium. Asterisks represent p< 0.05. Three further alleles with different numbers of repeats w
number of individuals (n ¼ 25) from the ALSPAC cohort and were thus excluded from the statistical
aThe number of heterozygous babies with paternally inherited RS1.
bThe number of heterozygous babies with maternally inherited RS1.
cThe meta-analysis of all three cohorts.
The American Journal offurther investigated the ALSPAC cohort
to see whether the maternal genotypes
would have an effect on the babies0 birth
weight. Because we cannot determine the
parental origin of the RS1 allele of the
heterozygous mothers without the grand-
parents0 samples, we instead compared the
effect of three maternal genotype groups
on the babies0 birth weight by using the
homozygous RS2/RS2 group (n ¼ 465) as
the baseline. To test this, we used a linear-regression model corrected for the same covariates
described in the previous analysis. Our analysis showed
that the heterozygous group (n ¼ 529) had a low impact
on the babies0 birth weight (þ0.3 g; p ¼ 0.99; 95% CI ¼
69–70); this result was expected because half of the
babies should inherit a paternal RS1. However, when
the mothers were homozygous for RS1 (n ¼ 61), the babies
were found to be 155 g heavier (p¼ 0.04; 95% CI¼ 9–300),
indicating that maternal genotypes have an additional
influence on fetal growth potentially through the intra-
uterine environment. This change is of similar magnitude
to the reduction caused by maternal smoking (Table S2).
Notably, the effect of heterozygous mothers on birth
weight was not midway between each homozygote, even
though half would be expected to carry the maternal
RS1. Instead, the homozygous RS1/RS1 group had consid-
erably more than twice the effect on birth weight than did
the heterozygous group. This suggests a three-generation
cumulative effect, given that a homozygous RS1/RS1
mother also inherits maternal RS1 from her mother.nalysis





ith heterozygous parents are uninformative for the parental
sted for the following covariates: gender, parity, maternal
uency had no evidence of deviation from the Hardy-Wein-
ere identified at the PHLDA2 RS locus in an extremely small
analysis.
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Figure 3. Meta-Analysis Showing the Relationship between
Birth Weight and PHLDA2 Promoter RS1 Effect
The data is depicted in a Forest plot; the 95% CI for each study is
represented by a horizontal line, and the estimated effect sizes are
shown as gray squares. The weight of the study in the meta-anal-
ysis is represented by the size of the squares. The scale used is in
grams (g). The diamond shape indicates the mean and 95% CI
for the total estimate of the effect. Both random- and fixed-effect
models produced the same results, and the plot represents the
results from the fixed-effect model.Alternatively, homozygous RS1/RS1 mothers could also
affect babies0 birth weight by influencing the circulating
PHLDA2 protein/mRNA levels in the maternal blood,
given that PHLDA2 shows biallelic expression in adult
blood.14
Maternal inheritance of RS1 did not affect the placental
weight (þ2.5 g; p ¼ 0.93; 95% CI ¼ 62–67) but did
have a small and statistically-significant influence on
head circumference (þ0.23 cm; p ¼ 0.04; 95% CI ¼ 0.01–
0.45). Interestingly, although the RS1 sequence is con-
served in monkeys, the duplicated RS2 allele seems to be
exclusive to humans (Figure S1). This implies an evolu-
tionary role in human reproductive success. Consistent
with the conflict hypothesis, maternal PHLDA2 RS1 is asso-
ciated with both increased growth of the baby and head
circumference. Conversely, the net effect of the common
(RS2/RS2) allele in humans is limited birth weight and
head circumference, an effect which might provide an
evolutionary advantage—protecting the mother and her
birth canal.
Given the perinatal and life-long health complications
associated with very low birth weight,1,2,15 a number of
studies have investigated the genetic contribution of puta-
tive growth-regulating genes, including the imprinted
genes IGF2 (MIM 147470) and H19 (MIM 103280).16–19
Genome-wide linkage or association studies have located
several loci associated with birth weight,20–23 although
none have yet been directly associated with actual gene
function. PHLDA2 has not previously been detected in
these screens, perhaps as a result of the complexity intro-
duced by the parent-of-origin effect but also because
PHLDA2 RS1 is not in linkage disequilibrium with nearby
SNPs and is therefore not well-represented on the genotyp-
ing platforms used. In addition, our study maximizes the
information content for this allele because we specifically
genotyped all informative individuals for what is essen-
tially the functional and presumably causal variant. The
biochemical function of PHLDA2 remains unknown. It is
a small cytoplasmic protein that binds to phosphoinosi-718 The American Journal of Human Genetics 90, 715–719, April 6, 2tide lipids via its PH domain.24 A recent study showed a
relationship between PHLDA2 expression and lower
growth velocity of the fetal femur; this relationship
suggests that PHLDA2 possibly plays a role in bone devel-
opment.25 Although increased Phlda2 expression in
transgenic mice resulted in a smaller placenta and a corre-
sponding reduction in birth weight,5 we could not
replicate this finding on the human placenta either in
a comparative study with PHLDA2 expression11 or indi-
rectly via association with the promoter RS genotype.
Nevertheless, a profound effect on the babies0 birth weight
was still detected, suggesting that placental weight was not
the predominant regulatory factor. It also appears that
this effect is controlled through the maternal expression
of the gene, which is consistent with the conflict hypoth-
esis and is mediated by the maternal genetic inheritance at
the DNA level in the promoter. This provides the first
example of a maternal genetic effect working together
with a maternally driven epigenetic effect. We suspect it
will be the first of many examples once further details of
the interactions of the genome with the epigenome are
unraveled. The PHLDA2 promoter RS and its expression
might serve as a useful genetic biomarker that can be
used to predict birth size. Further insight into the function
of PHLDA2 along with other imprinted genes will help us
understand the genetic basis of fetal growth as well as
the common and serious complications—such as IUGR—
of pregnancy.Supplemental Data
Supplemental Data include three figures and three tables and can
be found with this article online at http://www.cell.com/AJHG.Acknowledgments
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